EICHORPublic-registry site landscape for NCT02562443, “Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA”, a Myelodysplastic Syndrome study sponsored by Traws Pharma, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT02562443 (registry record) |
| Study title | Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA |
| Official title | A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent |
| Sponsor | Traws Pharma, Inc. |
| Condition(s) | Myelodysplastic Syndrome; MDS; Refractory Anemia With Excess Blasts; RAEB |
| Phase | PHASE3 |
| Listed sites | 158 |
| Intervention(s) | rigosertib, Any approved or standard-of-care therapy, best supportive care (BSC) |
| Site countries | United States, Australia, Austria, Belgium, Canada, Croatia, Czechia, Estonia, France, Germany, Hungary, India |
Patient-friendly overview of this study: eichor.com/study/NCT02562443.
Eichor generates a preliminary site-risk snapshot for NCT02562443 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
